by Nathalie Dusserre, Research Engineer, ART BioPrint (Inserm U1026, BioTis, Université de Bordeaux, France)
Laser-Assisted Bioprinting (LAB) technology, due to its unprecedented cell printing resolution and precision, is an attractive tool for the in situ printing of a bone substitute. We have previously shown that LAB can be used to induce bone regeneration through the in situ printing of mesenchymal stromal cells, associated with collagen and nano-hydroxyapatite, in a calvaria defect model in mice. In this model, different cell printing geometries proved to impact differently the process of bone tissue regeneration.
Since vascularization plays a crucial role in bone formation and regeneration process, a new study was designed to organize endothelial cells in situ, in the same mouse calvaria bone defect. The objective was to generate a pre-vascularization with a defined architecture, to further promote in vivo bone regeneration. In this study, Laser-Assisted Bioprinting was used to pattern red fluorescent protein-labeled endothelial cells into a mouse calvaria bone defect of critical size, prefilled with collagen containing mesenchymal stem cells and vascular endothelial growth factor. LAB technology allowed safe and controlled in vivo printing of different cell patterns.
In situ printing of endothelial cells gave rise to organized microvascular networks into bone defects. At two months, vascularization rate and bone regeneration rate showed statistically significant differences between the ‘random seeding’ condition and both the ‘disc’ and ‘crossed circle’ patterns. These results indicate that in vivo LAB is a valuable tool to generate in situ pre-vascularization with a defined configuration and to promote bone regeneration. They also demonstrate the importance of properly designing the original bioprinted architecture to induce the desired regeneration process.
Nathalie Dusserre1, Olivia Kérourédan2,3,4, Davit Hakobyan1, Murielle Remy2,3, Sophia Ziane2,3,4, Jean-Christophe Fricain1,2,3,4, Samantha Delmond5, Noëlie B Thébaud2,3,4, Raphaël Devillard2,3,4
1 ART BioPrint, INSERM, U1026, F-33076 Bordeaux, France, 2 INSERM, Bioingénierie Tissulaire, U1026, F-33076 Bordeaux, France,
3 Université de Bordeaux, Bioingénierie Tissulaire, U1026, F-33076 Bordeaux, France, 4 CHU de Bordeaux, Services d’Odontologie et de Santé Buccale, F-33076 Bordeaux, France , 5 CHU de Bordeaux, INSERM, CIC1401, F-33000 Bordeaux, France
about Nathalie Duserre
Dr. Dusserre is now part of a multidisciplinary team promoting the development of bioprinting technologies, the Accelerator of Research in Technology (or ART) BioPrint. The ART BioPrint, developed by the French National Institute of Health and Medical Research (or Inserm), is embedded within a research unit specialized in Tissue Engineering, located at the Université de Bordeaux, in France, and focuses on bioprinting technologies assisted by microextrusion, inkjet, and laser-assisted bioprinting technologies.